Top

Published in:

31-05-2022 | Cardiac Amyloidosis | International Corner

Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group

Authors: Fernando Mut, MD, FASNC, Isabel Carvajal, MD, Jorge Camilletti, MD, PhD, FACC, Juan Erriest, MD, PhD, Erick Alexanderson, MD, FACC, FESC, Gabriel Blacher Grossman, MD, PhD, FASNC

Published in: Journal of Nuclear Cardiology | Issue 4/2023

Abstract

Background

Cardiac amyloidosis (CA) is an under-diagnosed disease presenting as a restrictive cardiomyopathy with high morbidity and mortality. Wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) is mostly seen in elderly patients, with increasing prevalence as life expectancy is growing. New diagnostic imaging techniques and treatments allow for a better prognosis, but lack of clinical awareness delays timely diagnosis and appropriate management. Our purpose was to investigate the knowledge of clinicians regarding ATTR-CM and to assess the availability of imaging resources in the Latin-American region.

Methods and Results

Two online surveys were distributed among clinicians and nuclear medicine professionals, respectively: one asking about awareness of CA in different clinical scenarios, and the other about the availability of diagnostic resources and studies performed. 406 responses were received for the first survey and 82 for the second, representing 17 and 14 countries, respectively. A significant lack of awareness was identified among clinicians, although appropriate diagnostic resources are generally available. Survey data showed that very few patients are evaluated for ATTR-CM in most Latin-American countries.

Conclusions

The surveys demonstrated the need for educational programs and other measures to increase clinical awareness and early detection of CA, so patients receive timely treatment and management of the disease.

Available only for authorised users

Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond) 2018;18:s30‐5. https://doi.org/10.7861/clinmedicine.18-2-s30.CrossRefPubMed

Ash S, Shorer E, Ramgobin D, Vo M, Gibbons J, Golamari R. Cardiac amyloidosis—A review of current literature for the practicing physician. Clin Cardiol 2021;44:322‐31. https://doi.org/10.1002/clc.23572.CrossRefPubMedPubMedCentral

Picken MM. The pathology of amyloidosis in classification: A review. Acta Haematol 2020;143:322‐34. https://doi.org/10.1159/000506696.CrossRefPubMed

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554‐68. https://doi.org/10.1093/eurheartj/ehab072.CrossRefPubMedPubMedCentral

Mesquita ET, Jorge AJL, Souza CV Jr, Andrade TR. Cardiac amyloidosis and its new clinical phenotype: Heart failure with preserved ejection fraction. Arq Bras Cardiol 2017;109:71‐80. https://doi.org/10.5935/abc.20170079.CrossRefPubMedPubMedCentral

Oghina S, Bougouin W, Bézard M, Kharoubi M, Komajda M, Cohen-Solal A, et al. The impact of patients with cardiac amyloidosis in HFpEF trials. JACC Heart Fail 2021;9:169‐78. https://doi.org/10.1016/j.jchf.2020.12.005.CrossRefPubMed

Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 2014;21:271‐83. https://doi.org/10.1007/s12350-013-9800-5.CrossRefPubMed

Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: A practical approach. JACC Cardiovasc Imaging 2020;13:1368‐83. https://doi.org/10.1016/j.jcmg.2019.07.015.CrossRefPubMed

Macedo AVS, Schwartzmann PV, de Gusmão BM, Melo MDT, Coelho-Filho OR. Advances in the treatment of cardiac amyloidosis. Curr Treat Options Oncol 2020;21:36. https://doi.org/10.1007/s11864-020-00738-8.CrossRefPubMedPubMedCentral

10.

Gietel-Basten S, Saucedo SEG, Scherbov S. Prospective measures of aging for Central and South America. PLoS ONE 2020;15:e0236280. https://doi.org/10.1371/journal.pone.0236280.CrossRefPubMedPubMedCentral

11.

Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen Howard J, et al. Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association. Circulation 2020;142:e7-22. https://doi.org/10.1161/CIR.0000000000000792.CrossRefPubMed

12.

Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019;7:709‐16. https://doi.org/10.1016/j.jchf.2019.04.010.CrossRefPubMed

13.

Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019;140:16‐26. https://doi.org/10.1161/CIRCULATIONAHA.118.038169.CrossRefPubMed

14.

Simões MV, Fernandes F, Marcondes-Braga FG, Scheinberg P, de Barros CE, Rohde LE, et al. Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca – 2021. Arq Bras Cardiol 2021;117:561‐98. https://doi.org/10.36660/abc.20210718.CrossRefPubMedPubMedCentral

15.

Rayhan RU, Zheng Y, Uddin E, Timbol C, Adewuyi O, Baraniuk JN. Administer and collect medical questionnaires with Google documents: A simple, safe, and free system. Appl Med Inform 2013;33:12‐21.PubMedPubMedCentral

16.

Mircsof D. Diagnosis of amyloidosis: A survey of current awareness and clinical challenges among cardiologists in Switzerland. Cardiol Ther 2020;9:127‐38. https://doi.org/10.1007/s40119-019-00160-8.CrossRefPubMedPubMedCentral

17.

Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber WA, et al. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy. J Nucl Cardiol 2017;24:1094‐7. https://doi.org/10.1007/s12350-016-0478-3.CrossRefPubMed

18.

Andrade C. The limitations of online surveys. Indian J Psychol Med 2020;42:575‐6. https://doi.org/10.1177/0253717620957496.CrossRefPubMedPubMedCentral

Title: Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group
Authors: Fernando Mut, MD, FASNC
Isabel Carvajal, MD
Jorge Camilletti, MD, PhD, FACC
Juan Erriest, MD, PhD
Erick Alexanderson, MD, FACC, FESC
Gabriel Blacher Grossman, MD, PhD, FASNC
Publication date: 31-05-2022
Publisher: Springer International Publishing
Keyword: Cardiac Amyloidosis
Published in: Journal of Nuclear Cardiology / Issue 4/2023
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-022-03005-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group

Abstract

Background

Methods and Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2023

LV functional evaluation on 11C-PiB PET/CT in cardiac amyloidosis

PET myocardial perfusion imaging in superior vena cava syndrome

Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis

Extracardiac findings with increased perfusion during clinical O-15-H2O PET/CT myocardial perfusion imaging: A case series

Using standardized uptake values in pyrophosphate imaging

A story of resolved ischemia from anomalous coronary arteries as told by PET/CT